Trade Names:Amevive- Powder for injection, lyophilized 15 mg
Interferes with lymphocyte activation.
Bioavailability of alefacept after IM injection is 63%.
The mean Vd of alefacept is 94 mL/kg after IV injection.
The mean elimination t ½ and Cl are approximately 270 h and 0.25 mL/kg, respectively, following IV injection.
Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
HIV infection; hypersensitivity to any component of the product.
IV/IM 7.5 mg once weekly as an IV bolus or 15 mg once weekly as an IM injection for 12 weekly injections. After a minimum of a 12-wk interval since the initial treatment, re-treatment with an additional 12-wk course may be initiated, provided the CD4+ T-lymphocyte counts are within the normal range.
Refrigerate dose tray with lyophilized powder at 36° to 46°F. Store in original carton until time of use. Protect from light. Use reconstituted product immediately or within 4 h if stored in refrigerator. Discard if not used within 4 h of reconstitution.
None well documented.
None well documented.
Acute liver failure, asymptomatic transaminase elevation, decompensation of cirrhosis with liver failure, fatty infiltration of the liver, hepatitis (postmarketing).
Increased cough, pharyngitis.
Accidental injury, chills, hypersensitivity reactions (eg, anaphylactic reactions, angioedema, urticaria), injection-site reactions (eg, bleeding, edema, inflammation, mass, nonspecific reaction, pain, skin hypersensitivity), lymphopenia, malignancies, myalgia, serious infections.
Ensure CD4+ T-lymphocyte counts are determined prior to starting therapy and every 2 wk throughout entire 12-wk course of therapy.
Category B .
Safety and efficacy not established.
Use with caution because the incidence of infection and certain malignancies is higher.
May occur. Discontinue therapy in patients who develop significant clinical signs of liver injury.
Do not use with other immunosuppressive agents or phototherapy.
Do not initiate therapy in patients with a CD4+ T-lymphocyte count below normal. Withhold therapy if CD4+ T-lymphocyte count is below 250 cells/mcL. Discontinue therapy if CD4+ T-lymphocyte counts are below 250 cells/mcL for 1 mo.
May increase the risk of malignancies.
May increase the risk of infection and reactivate latent, chronic infections.
Arthralgia, chills, headache, sinusitis.
Copyright © 2009 Wolters Kluwer Health.